Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Capital Expenditures (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Capital Expenditures for 13 consecutive years, with $101000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Capital Expenditures rose 46.38% to $101000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $292000.0, a 79.14% increase, with the full-year FY2025 number at $292000.0, up 79.14% from a year prior.
  • Capital Expenditures was $101000.0 for Q4 2025 at Niagen Bioscience, up from $24000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $265000.0 in Q2 2021 to a low of $2000.0 in Q4 2021.
  • A 5-year average of $67300.0 and a median of $43500.0 in 2021 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: tumbled 99.26% in 2021, then soared 8500.0% in 2022.
  • Niagen Bioscience's Capital Expenditures stood at $2000.0 in 2021, then skyrocketed by 8500.0% to $172000.0 in 2022, then crashed by 87.79% to $21000.0 in 2023, then surged by 228.57% to $69000.0 in 2024, then surged by 46.38% to $101000.0 in 2025.
  • Per Business Quant, the three most recent readings for NAGE's Capital Expenditures are $101000.0 (Q4 2025), $24000.0 (Q3 2025), and $135000.0 (Q2 2025).